“Global Vaccine Contract Manufacturing market set to grow to $2.9bn by 2023” says new Visiongain report

02 April 2019
Pharma

Visiongain has launched a new pharma report Vaccine Contract Manufacturing Market Report : Paediatric Vaccines, Adult Vaccines, Influenza Vaccines, Therapeutic Vaccines, Downstream Processing, Fill & Finish Operations, Analytical & QC Studies, Packaging, Upstream Processing, Mammalian Expression Systems, Bacterial Expression Systems, Yeast Expression Systems, Baculovirus/Insect Expression Systems, Other Upstream Processing.

The vaccine manufacturing sector has traditionally been conservative in its approach, relying on traditional methods for vaccine production. The vaccine shortages of recent years that were caused by national pandemics (such as avian flu) highlighted the shortcomings of some of these production methods. The increasing demand for vaccines will make it vital for the vaccine manufacturing industry to develop more-efficient methods for producing vaccines.

The lead analyst of the report commented "Major fluctuations in demand are seen in the case of influenza, as was seen during pandemics over the last decade. The shortage of the number of doses was attributed to the slow and low-yielding traditional egg-based manufacturing technology that has been used for several decades by vaccine manufacturers. This egg-based manufacturing method has been meeting the demand for seasonal influenza vaccines but has been inefficient for meeting the rise in the global demand during pandemics.

Several small and large vaccine manufacturers are now exploring innovative technology platforms for improving the scale of production of the influenza vaccine. Most of the recent developments in manufacturing platforms have been for this vaccine type. Thus, the vaccine manufacturing techniques are evolving, and this will stimulate the growth of the vaccine contract manufacturing market during the forecast period."

Leading companies featured in the report include AbbVie, Baxter BioPharma Solutions, Boehringer Ingelheim, Catalent, Charles River Laboratories, Evonik Degusa, IDT Biologika, Lonza, Meridian Life Science, Nipro Corporation and others.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes ePharmacy Market Report 2021-2031

The growth in online shopping has been driven by a rapid rise in the number of smartphones, broadband connections and innovative payment products, although security remains the biggest concern. With the evolving market dynamics, merchants’ payment needs are also changing.

06 May 2021

Read

Visiongain Publishes Protein Labelling Reagents for Research Use Only (RUO) Market Report 2021-2031

Increasing investment in R&D for proteomics research, by both public and private organizations, is one of the major contributors to the growth of the protein labelling reagents market. The increasing prevalence of chronic diseases is also expected to contribute to the growth of this market.

05 May 2021

Read

Visiongain Publishes Aptamer Technologies Market Report 2021-2031

Over the last few years, the aptamers has gained widespread attention due to the technological advancements and growth in understanding of the oligonucleotide therapeutics that inhabit the human body.

29 April 2021

Read

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031

Rising prevalence of inflammatory bowel disease including Crohn’s disease and ulcerative colitis; raising awareness for IBD in developing countries; escalating investment in drug R&D by pharmaceutical companies; new product launches worldwide, growing chronic diseases healthcare awareness are some of the major factors that boosting the growth of global IBD drugs market.

29 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever